Healthcare & Pharma • Quantitative Market Data & AI Analytics
| Metric / Indicator | Current Reading | AI Action Verdict |
|---|---|---|
| RSI (14) Relative Strength | 53.52 | 🔒 Unlock AI Verdict |
| MACD (12, 26, 9) Level / Signal | +1.070 / +0.408 | 🔒 Unlock AI Verdict |
| Bollinger Bands (20, 2) & EMA (50/200) | 392.79 - 425.53 | BULLISH TREND |
| AI News Sentiment & Momentum Score | 82.5 / 100 | High Accumulation |
| AI Hybrid Probability & 30D Target Range | 384.61 - 458.26 | STRONG BUY |
You are viewing raw mathematical RSI (53.5) and MACD (+1.070) computations. To unlock AI interpretation, Bullish/Bearish ratings, Bollinger Bands, Executive Insider Trades, and 30-Day Statistical Trend Charts for Amgen, download the TradeGPT Android app.
Download on Google Play
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read more Google Play
